Multicenter Clinical Validation of PITX2 Methylation as a Prostate Specific Antigen Recurrence Predictor in Patients With Post-Radical Prostatectomy Prostate Cancer
- 17 May 2010
- journal article
- research article
- Published by Ovid Technologies (Wolters Kluwer Health) in Journal of Urology
- Vol. 184 (1), 149-156
- https://doi.org/10.1016/j.juro.2010.03.012
Abstract
Radical prostatectomy is potentially curative in patients with clinically localized prostate cancer. However, biochemical recurrence affects 15% to 30% of men who undergo radical prostatectomy. We previously reported the prognostic potential of PITX2 gene promoter methylation using conventional assays. In the current study we validated PITX2 methylation status as a biochemical recurrence predictor after radical prostatectomy using a novel microarray based platform in a multi-institutional setting. PITX2 methylation status was assessed in formalin fixed, paraffin embedded prostatectomy tumor tissue samples from 476 patients from a total of 4 institutions on customized EpiChip™ PITX2 microarrays. Associations between PITX2 methylation and biochemical recurrence were assessed using the log rank test and Cox regression controlling for prostate cancer features. On multivariate analysis men with high methylation status were at significantly higher risk for biochemical recurrence than those with low methylation status (HR 3.0, 95% CI 2.0–4.5, p −5). The biochemical recurrence-free survival rate 5 years after surgery was 85% and 61% in the low and high methylation groups, respectively. In men with pathological Gleason 7 tumors the relative risk of biochemical recurrence was twice as high for high than for low PITX2 methylation (HR 2.0, 95% CI 1.2–3.3, p = 0.005). PITX2 methylation status assessed by EpiChip PITX2 identifies patients with prostate cancer who are most likely to have biochemical recurrence. This test independently adds to the prognostic information provided by standard clinicopathological analysis, improving prostatectomy case stratification into those at high and low risk for biochemical recurrence. This new clinical tool would be of particular benefit to assess intermediate risk cases (Gleason 7) in which risk stratification remains a challenge.Keywords
This publication has 26 references indexed in Scilit:
- Development of a Diagnostic Microarray Assay to Assess the Risk of Recurrence of Prostate Cancer Based on PITX2 DNA MethylationThe Journal of Molecular Diagnostics, 2010
- Adjuvant Radiotherapy for Pathological T3N0M0 Prostate Cancer Significantly Reduces Risk of Metastases and Improves Survival: Long-Term Followup of a Randomized Clinical TrialJournal of Urology, 2009
- Adjuvant radiotherapy after radical prostatectomy shows no ability to improve rates of overall and cancer‐specific survival in a matched case‐control studyBJU International, 2009
- Identification of a panel of sensitive and specific DNA methylation markers for squamous cell lung cancerMolecular Cancer, 2008
- Improved Prediction of Disease Relapse after Radical Prostatectomy through a Panel of Preoperative Blood-Based BiomarkersClinical Cancer Research, 2008
- Impact of a Multidisciplinary Continuous Quality Improvement Program on the Positive Surgical Margin Rate after Laparoscopic Radical ProstatectomyEuropean Urology, 2006
- Nuclear Factor-κB Nuclear Localization Is Predictive of Biochemical Recurrence in Patients with Positive Margin Prostate CancerClinical Cancer Research, 2004
- Early Versus Delayed Hormonal Therapy for Prostate Specific Antigen Only Recurrence of Prostate Cancer After Radical ProstatectomyJournal of Urology, 2004
- Breast and Prostate Cancer: An Analysis of Common Epidemiological, Genetic, and Biochemical FeaturesEndocrine Reviews, 1998
- Cloning and characterization of a novel bicoid-related homeobox transcription factor gene, RIEG, involved in Rieger syndromeNature Genetics, 1996